Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations

References

• Kravarusic J, Aleppo G. Diabetes technology use in adults with type 1 and type 2 diabetes. Endocrinol Metab Clin North Am. 2020;49(1):37–55. PMID: 31980120. doi:10.1016/j.ecl.2019.10.006
   PubMed Web of Science ®Google Scholar
• Rodbard, D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 2017;19:S25–37
   PubMed Web of Science ®Google Scholar
• Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017; (4):947–951. PMID: 28616804; PMCID: PMC5544617. doi:10.1007/s13300-017-0281-4
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth T, Ruedy K, et al.; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371–378. PMID: 28118453. doi:10.1001/jama.2016.19975
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hessler D, Ruedy KJ, Beck RW; DIAMOND Study Group. The Impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736–741. PMID: 28389582. doi:10.2337/dc17-0133
   PubMed Web of Science ®Google Scholar
• El Sayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association. 7. Diabetes technology: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S111–S127. doi:10.2337/dc23-S007
   PubMedGoogle Scholar
• Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2016;101(11):3922–3937. doi:10.1210/jc.2016-2534
   PubMed Web of Science ®Google Scholar
• Grunberger G, Sherr J, Allende M, et al. American association of clinical endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27:505e537. doi:10.1016/j.eprac.2021.04.008
   Web of Science ®Google Scholar
• Christiansen MP, Klaff LJ, Brazg R, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197–206. PMID: 29381090; PMCID: PMC5867508. doi:10.1089/dia.2017.0142
   PubMed Web of Science ®Google Scholar
• Medtronic Guardian Connect App, Medtronic, Inc. Available from: https://hcp.medtronic-diabetes.com.au/guardian-connect#collapseOne1. Accessed February 28, 2023.
   Google Scholar
• Dexcom G5 continuous glucose monitoring systems user guide. Dexcom, Inc; 2018. Available from: https://s3-us-west-2.amazonaws.com/dexcompdf/G5-Mobile-Users-Guide.pdf. Accessed February 28, 2023.
   Google Scholar
• DexcomG6 continuous glucose monitoring systems user guide. Dexcom, Inc; 2018. Available from: https://s3-us-west.amazonaws.com/dexcompdf/Using-Your-G6.pdf. Accessed February 28, 2023.
   Google Scholar
• Eversense Mobile App, Senseonics, Inc. . Available from: https://www.ascensiadiabetes.com/eversense/eversense-cgm-system/mobile-app/. Accessed February 28, 2023.
   Google Scholar
• Abbott Diabetes Care, Inc. FreeStyle libre. Available from: https://www.freestylelibre.us/system-overview/freestyle-14-day.html. Accessed February 28, 2023.
   Google Scholar
• FreeStyle Libre 3. Abbott Diabetes Care, Inc. Available from: : https://www.freestyle.abbott/us-en/products/freestyle-libre-3.html. Accessed February 6, 2023.
   Google Scholar
• Dexcom G7, Dexcom, Inc. Available from: https://www.dexcom.com/en-us/g7-fda. Accessed February 6, 2023.
   Google Scholar
• FreeStyle Libre 2. Abbott Diabetes Care, Inc. Available from: https://abbott.mediaroom.com/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe. Accessed February 28, 2023.
   Google Scholar
• Edelman SV, Argento NB, Pettus J, et al. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41(11):2265–2274. doi:10.2337/dc18-1150
   PubMed Web of Science ®Google Scholar
• Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40:1622–1630. doi:10.2337/dc17-1624
   PubMed Web of Science ®Google Scholar
• Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi:10.2337/dci19-0028
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–2280. doi:10.2337/dc18-1581
   PubMed Web of Science ®Google Scholar
• van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016; (11):893–902. PMID: 27641781. doi:10.1016/S2213-8587(16)30193-0
   PubMed Web of Science ®Google Scholar
• Pratley, RE, Kanapka, LG, Rickels, MR et al WISDM Study Group. Wireless Innovation for Seniors With Diabetes Mellitus (WISDM) Study Group. Effects of Continuous Glucose monitoring on Hypoglycemia in Older Adults with Type 1 Diabetes. A Randomized Clinical Trial., JAMA. 2020,Jun 16;323(23):2397–2406. PMID 32543682. doi:10.1001/jama/2020/6928
   PubMed Web of Science ®Google Scholar
• Miller KM, Kanapka LG, Rickels MR, et al. Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. Diabetes Technol Ther. 2022;24(6):424–434. PMID: 35294272; PMCID: PMC9208859. doi:10.1089/dia.2021.0503
   PubMed Web of Science ®Google Scholar
• Mangrola D, Cox C, Furman AS, Krishnan S, Karakas SE. Self-blood glucose monitoring underestimates hyperglycemia and hypoglycemia as compared to continuous glucose monitoring in type 1 and type 2 diabetes. Endocr Pract. 2018;24(1):47–52. PMID: 29144814. doi:10.4158/EP-2017-0032
   PubMed Web of Science ®Google Scholar
• Ólafsdóttir AF, Polonsky W, Bolinder J, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther. 2018;20(4):274–284. PMID: 29608107; PMCID: PMC5910048. doi:10.1089/dia.2017.0363
   PubMed Web of Science ®Google Scholar
• Volcansek S, Lunder M, Janež A. Acceptability of continuous glucose monitoring in elderly diabetes patients using multiple daily insulin injections. Diabetes Technol Ther. 2019;21(10):566–574. PMID: 31335199. doi:10.1089/dia.2019.0131
   PubMed Web of Science ®Google Scholar
• Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):6–10. PMID: 30575413. doi:10.1089/dia.2018.0257
   PubMed Web of Science ®Google Scholar
• Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care. 2022;45(3):750–753. PMID: 35018417. doi:10.2337/dc21-2004
   PubMed Web of Science ®Google Scholar
• Aleppo G, Ruedy KJ, Riddlesworth TD, et al.; REPLACE-BG Study Group. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017;40(4):538–545. PMID: 28209654; PMCID: PMC5864100. doi:10.2337/dc16-2482
   PubMed Web of Science ®Google Scholar
• Lin T, Manfredo JA, Illesca N, et al. Improving CGM uptake in underserved youth with type 1 diabetes: the IMPACT study. Diabetes Technol Ther. 2022. doi:10.1089/dia.2022.0347
   PubMedGoogle Scholar
• Advani A. Positioning time in range in diabetes management. Diabetologia. 2020;63(2):242–252. doi:10.1007/s00125-019-05027-0
   PubMed Web of Science ®Google Scholar
• Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882–2885. doi:10.2337/dc20-0909
   PubMed Web of Science ®Google Scholar
• Yoo JH, Choi MS, Ahn J, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther. 2020;22(10):768–776. PMID: 32167394. doi:10.1089/dia.2019.0499
   PubMed Web of Science ®Google Scholar
• Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400–405. PMID: 30352896; PMCID: PMC6905478. doi:10.2337/dc18-1444
   PubMed Web of Science ®Google Scholar
• Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370–2376. PMID: 30201847. doi:10.2337/dc18-1131
   PubMed Web of Science ®Google Scholar
• Li F, Zhang Y, Li H, et al. TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. Diabetes Res Clin Pract. 2020;166:108289. PMID: 32615278. doi:10.1016/j.diabres.2020.108289
   PubMed Web of Science ®Google Scholar
• Szmuilowicz ED, Aleppo G. Stepwise approach to continuous glucose monitoring interpretation for internists and family physicians. Postgrad Med. 2022;134(8):743–751. PMID: 35930313. doi:10.1080/00325481.2022.2110507
   PubMed Web of Science ®Google Scholar
• Mensh BD, Wisniewski NA, Neil BM, Burnett DR. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol. 2013;7(4):863–870. doi:10.1177/193229681300700408
   PubMedGoogle Scholar
• Laffel L. Improved accuracy of continuous glucose monitoring systems in pediatric patients with diabetes mellitus: results from two studies. Diabetes Technol Ther. 2016;18(Suppl 2):S223–S233. doi:10.1089/dia.2015.0380
   PubMedGoogle Scholar
• Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care. 2003;26(8):2405–2409. doi:10.2337/diacare.26.8.2405
   PubMed Web of Science ®Google Scholar
• Zaharieva DP, Turksoy K, McGaugh SM, et al. Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes. Diabetes Technol Ther. 2019;21(6):313–321. doi:10.1089/dia.2018.0364
   PubMed Web of Science ®Google Scholar
• Maahs DM, DeSalvo D, Pyle L, et al. Effect of Acetaminophen on CGM glucose in an outpatient setting. Diabetes Care. 2015;38(10):e158–e159. doi:10.2337/dc15-1096
   PubMed Web of Science ®Google Scholar
• Szmuilowicz ED, Aleppo G. Interferent effect of hydroxyurea on continuous glucose monitoring. Diabetes Care. 2021;44(5):e89–e90. doi:10.2337/dc20-3114
   PubMed Web of Science ®Google Scholar
• Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014;37(10):2702–2709. doi:10.2337/dc14-0303
   PubMed Web of Science ®Google Scholar
• Englert K, Ruedy K, Coffey J, et al. Skin and adhesive issues with continuous glucose monitors: a sticky situation. J Diabetes Sci Technol. 2014;8(4):745–751. doi:10.1177/1932296814529893
   PubMedGoogle Scholar
• Can I use Dexcom G6 during an MRI, CT scan, or diathermy treatment?; 2020. Available from: https://www.dexcom.com/faqs/use-dexcom-g6-during-mri-ct-scan-or-diathermy. Accessed February 28, 2023.
   Google Scholar
• Forlenza GP, Argento NB, Laffel LM. Practical considerations on the use of continuous glucose monitoring in pediatrics and older adults and nonadjunctive use. Diabetes Technol Ther. 2017;19(S3):S13–S20. doi:10.1089/dia.2017.0034
   PubMedGoogle Scholar
• Kubiak T, Priesterroth L, Barnard-Kelly KD. Psychosocial aspects of diabetes technology. Diabet Med. 2020;37(3):448–454. doi:10.1111/dme.14234
   PubMed Web of Science ®Google Scholar
• Isaacs D, Bellini NJ, Biba U, Cai A, Close KL. Health care disparities in use of continuous glucose monitoring. Diabetes Technol Ther. 2021;23(S3):S81–S87. doi:10.1089/dia.2021.0268
   PubMedGoogle Scholar
• Odugbesan O, Addala A, Nelson G, et al. Implicit racial-ethnic and insurance-mediated bias to recommending diabetes technology: insights from T1D exchange multicenter pediatric and adult diabetes provider cohort. Diabetes Technol Ther. 2022;24(9):619–627. doi:10.1089/dia.2022.0042
   PubMed Web of Science ®Google Scholar
• Addala A, Hanes S, Naranjo D, Maahs DM, Hood KK. Provider implicit bias impacts pediatric type 1 diabetes technology recommendations in the United States: findings from The Gatekeeper Study. J Diabetes Sci Technol. 2021;15(5):1027–1033. doi:10.1177/19322968211006476
   PubMedGoogle Scholar
• Health equity and diabetes technology: a study of access to continuous glucose monitors by payer and race executive summary. Available from: https://diabetes.org/sites/default/files/2021-10/ADA%20CGM%20Utilization%20White%20Paper.pdf. Accessed February 28, 2023.
   Google Scholar
• Agarwal S, Kanapka LG, Raymond JK, et al. Racial-ethnic inequity in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2020;105(8). doi:10.1210/clinem/dgaa236
   Web of Science ®Google Scholar
• Onisie O, Crocket H, de Bock M. The CGM grey market: a reflection of global access inequity. Lancet Diabetes Endocrinol. 2019;7(11):823–825. doi:10.1016/S2213-8587(19)30263-3
   PubMed Web of Science ®Google Scholar
• Borges U, Kubiak T. Continuous glucose monitoring in type 1 diabetes. J Diabetes Sci Technol. 2016;10(3):633–639. doi:10.1177/1932296816634736
   PubMedGoogle Scholar
• Klonoff DC. Cybersecurity for connected diabetes devices. J Diabetes Sci Technol. 2015;9(5):1143–1147. doi:10.1177/1932296815583334
   PubMedGoogle Scholar
• Messer LH, Tanenbaum ML, Cook PF, et al. Cost, hassle, and on-body experience: barriers to diabetes device use in adolescents and potential intervention targets. Diabetes Technol Ther. 2020;22(10):760–767. doi:10.1089/dia.2019.0509
   PubMed Web of Science ®Google Scholar
• Anderson JE, Gavin JR, Kruger DF. Current eligibility requirements for CGM coverage are harmful, costly, and unjustified. Diabetes Technol Ther. 2020;22(3):169–173. doi:10.1089/dia.2019.0303
   PubMed Web of Science ®Google Scholar
• Glucose Monitors. Centers for medicare & medicaid services; 2022. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822. Accessed October 10, 2022.
   Google Scholar
• Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the appropriate continuous glucose monitoring system - a practical approach. Eur Endocrinol. 2018;14(1):24–29. doi:10.17925/EE.2018.14.1.24
   PubMedGoogle Scholar
• Pickup JC, Ford Holloway M, Samsi K. Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives. Diabetes Care. 2015;38(4):544–550. doi:10.2337/dc14-1855
   PubMed Web of Science ®Google Scholar
• Davidson MB. Continuous glucose monitoring in patients with type 1 diabetes taking insulin injections. JAMA. 2017;317(4):363–364. doi:10.1001/jama.2016.20327
   PubMed Web of Science ®Google Scholar
• Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13(4):614–626. doi:10.1177/1932296818822496
   PubMedGoogle Scholar
• Perez-Guzman MC, Shang T, Zhang JY, Jornsay D, Klonoff DC. Continuous glucose monitoring in the hospital. Endocrinol Metab. 2021;36(2):240–255. doi:10.3803/EnM.2021.201
   Google Scholar
• Lu J, Ma X, Shen Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther. 2020;22(2):72–78. doi:10.1089/dia.2019.0251
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth TD, Ruedy KJ, et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(9):700–708. doi:10.1016/S2213-8587(17)30217-6
   PubMed Web of Science ®Google Scholar
• Nallicheri A, Mahoney KM, Gutow HA, Bellini N, Isaacs D. Review of automated insulin delivery systems for type 1 diabetes and associated time in range outcomes. touchREV Endocrinol. 2022;18(1):27–34. doi:10.17925/EE.2022.18.1.2
   PubMedGoogle Scholar
• Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278
   PubMed Web of Science ®Google Scholar
• Carlson AL, Martens TW, Johnson L, Criego AB. Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies. Diabetes Technol Ther. 2021;23(S3):S56–S65. doi:10.1089/dia.2021.0241
   PubMed Web of Science ®Google Scholar
• Bill Status of SB2969. Illinois general assembly. Available from: https://www.ilga.gov/legislation/BillStatus.asp?DocNum=2969&GAID=16&DocTypeID=SB&SessionID=110&GA=102. Accessed February 28, 2023.
   Google Scholar